Sage Journals: Discover world-class research

Retricted access

Research article

First published 2025-9

Theranostic performance of EGFR-targeted ceria-based nanoparticles on EGFR-positive cancers

Kochurani K Johnson, Pramod Koshy, Chantal Kopecky [...]

Journal of Biomaterials Applications

Open access

Review article

First published 2018

Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors

Vera Hirsh

Therapeutic Advances in Medical Oncology

Free access

Review article

First published 2010-09

The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations

Isamu Okamoto, Tetsuya Mitsudomi, Kazuhiko Nakagawa [...]

Therapeutic Advances in Medical Oncology

Free access

Case report

First published 2014-1

Advanced EGFR Mutation-Positive Non–Small-Cell Lung Cancer: Case Report,Literature Review,and Treatment Recommendations

Andrew Kuykendall, Alberto Chiappori

Cancer Control

Open access

Review article

First published 2019

First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the ‘real-world’ clinical setting

Keunchil Park, Darren Wan-Teck Lim, Isamu Okamoto [...]

Therapeutic Advances in Medical Oncology

Open access

Research article

First published 2018

Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer

Po-Lan Su, Yi-Lin Wu, Wei-Yuan Chang [...]

Therapeutic Advances in Medical Oncology

Open access

Research article

First published 2018

Dynamic changes in quality of life after three first-line therapies for EGFR mutation-positive advanced non-small-cell lung cancer

Szu-Chun Yang, Chien-Chung Lin, Wu-Wei Lai [...]

Therapeutic Advances in Medical Oncology

Open access

Research article

First published 2023

Rationale and design of phase II clinical trial of dual inhibition with ramucirumab and erlotinib in EGFR exon 19 deletion-positive treatment-naïve non-small cell lung cancer with high PD-L1 expression (SPIRAL-3D study)

Hayato Kawachi, Tadaaki Yamada, Akihiro Yoshimura [...]

Therapeutic Advances in Medical Oncology

Retricted access

Research article

First published 2009-03

Cetuximab Retargeting of Adenovirus via the Epidermal Growth Factor Receptor for Treatment of Intraperitoneal Ovarian Cancer

Joanne Morrison, Simon S. Briggs, Nicola K. Green [...]

Human Gene Therapy

Open access

Research article

First published 2018

A Gene Expression Signature Predicts Bladder Cancer Cell Line Sensitivity to EGFR Inhibition

Andrew Goodspeed, Annie Jean, Dan Theodorescu [...]

Bladder Cancer

Search results